Athenex, Inc. to Report Third Quarter 2020 Earnings Results on November 5, 2020
Athenex, Inc. (Nasdaq: ATNX) will release its third quarter 2020 financial results on November 5, 2020, prior to market opening. A conference call will follow at 8:00 AM ET for discussing the results and business updates. Participants can join by dialing 877-407-0784 (domestic) or 201-689-8560 (international) with the passcode 13711719. Athenex is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments through various platforms, including Orascovery and T-cell receptor-engineered T-cells.
- None.
- None.
BUFFALO, N.Y., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will release third quarter 2020 financial results on Thursday, November 5, 2020, before the market opens, and host a conference call and live audio webcast 8:00am Eastern Time to discuss financial results and provide a business update.
To participate in the call, dial 877-407-0784 (domestic) or 201-689-8560 (international) fifteen minutes before the conference call begins and reference the conference passcode 13711719. The live conference call and replay can also be accessed via audio webcast at the Investor Relations section of the Company’s website, located at http://ir.athenex.com/.
About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. The Company’s current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation therapy. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active treatments with improved tolerability profiles. Athenex has offices in the United States, Hong Kong, China, Taiwan, the United Kingdom and Latin America. For more information, please visit www.athenex.com.
CONTACTS
Steve Rubis
Athenex, Inc.
Email: stevenrubis@athenex.com
Daniel Lang, MD
Athenex, Inc.
Email: danlang@athenex.com
Tim McCarthy
LifeSci Advisors, LLC
Email: tim@lifesciadvisors.com
FAQ
When will Athenex release its third quarter 2020 financial results?
What time is the Athenex conference call scheduled for?
How can I participate in the Athenex conference call?
What is Athenex's focus in terms of drug development?
